[1] |
SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
|
[2] |
梁军, 李丽. 肝癌免疫治疗策略的进展与思考[J]. 中华消化外科杂志, 2021, 20(2): 184-190. DOI: 10.3760/cma.j.cn115610-20201228-00809.LIANG J, LI L. Progress and consideration of immunotherapy strategy for hepatocellular carcinoma[J]. Chin J Dig Surg, 2021, 20(2): 184-190. DOI: 10.3760/cma.j.cn115610-20201228-00809.
|
[3] |
YOH T, SEO S, TAURA K, et al. Surgery for recurrent hepatocellular carcinoma: achieving long-term survival[J]. Ann Surg, 2021, 273(4): 792-799. DOI: 10.1097/SLA.0000000000003358.
|
[4] |
SAPISOCHIN G, BRUIX J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 203-217. DOI: 10.1038/nrgastro.2016.193.
|
[5] |
中国医师协会器官移植医师分会, 中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.Branch of Organ Transplant Physician of Chinese Medical Doctor Association, Branch of Organ Transplantation of Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma (2018)[J]. J Clin Hepatol, 2019, 35(2): 275-280. DOI: 10.3969/j.issn.1001-5256.2019.02.008.
|
[6] |
RUDNICK SR, RUSSO MW. Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(3): 265-275. DOI: 10.1080/17474124.2018.1417035.
|
[7] |
刘召波, 栗光明. 肝移植术后肝癌复发防治进展[J]. 临床肝胆病杂志, 2021, 37(2): 267-271. DOI: 10.3969/j.issn.1001-5256.2021.02.006.LIU ZB, LI GM. Advances in the prevention and treatment of hepatocellular carcinoma recurrence after liver transplantation[J]. J Clin Hepatol, 2021, 37(2): 267-271. DOI: 10.3969/j.issn.1001-5256.2021.02.006.
|
[8] |
刘少儒, 许磊波. 肝癌肝移植术后复发转移的免疫治疗[J]. 器官移植, 2021, 12(3): 272-279. DOI: 10.3969/j.issn.1674-7445.2021.03.004.LIU SR, XU LB. Immunotherapy of recurrence and metastasis after liver transplantation for liver cancer[J]. Organ Transplant, 2021, 12(3): 272-279. DOI: 10.3969/j.issn.1674-7445.2021.03.004.
|
[9] |
KIM JM. Can hepatocellular carcinoma recurrence be prevented after liver transplantation?[J]. Clin Mol Hepatol, 2021, 27(4): 562-563. DOI: 10.3350/cmh.2021.0276.
|
[10] |
SATAPATHY SK, DAS K, KOCAK M, et al. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant[J]. Clin Transplant, 2018, 32(5): e13246. DOI: 10.1111/ctr.13246.
|
[11] |
GIAKOUSTIDIS AE, GIAKOUSTIDIS DE. Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma[J]. Immunotherapy, 2017, 9(2): 197-206. DOI: 10.2217/imt-2016-0110.
|
[12] |
中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J]. 器官移植, 2021, 12(1): 8-14, 28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)[J]. Organ Transplant, 2021, 12(1): 8-14, 28. DOI: 10.3969/j.issn.1674-7445.2021.01.002.
|
[13] |
FOERSTER F, HOPPE-LOTICHIUS M, VOLLMAR J, et al. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre[J]. United European Gastroenterol J, 2019, 7(6): 838-849. DOI: 10.1177/2050640619840221.
|
[14] |
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
|
[15] |
郑树森, 程启阳, 耿磊, 等. 肝癌肝移植术后肝癌复发研究新进展[J]. 中国普通外科杂志, 2019, 28(7): 773-778. DOI: 10.7659/j.issn.1005-6947.2019.07.001.ZHENG SS, CHENG QY, GENG L, et al. Tumor recurrence after liver transplantation for hepatocellular carcinoma: recent research progress[J]. Chin J Gen Surg, 2019, 28(7): 773-778. DOI: 10.7659/j.issn.1005-6947.2019.07.001.
|
[16] |
LI M, WANG Z, CAO J, et al. Risk factors and prognosis of patients with recurrent hepatocellular carcinoma who undergo liver re-resections[J]. Eur J Surg Oncol, 2019, 45(9): 1684-1690. DOI: 10.1016/j.ejso.2019.04.008.
|
[17] |
FERNANDEZ-SEVILLA E, ALLARD MA, SELTEN J, et al. Recurrence of hepatocellular carcinoma after liver transplantation: is there a place for resection?[J]. Liver Transpl, 2017, 23(4): 440-447. DOI: 10.1002/lt.24742.
|
[18] |
ROAYAIE S, BASSI D, TARCHI P, et al. Second hepatic resection for recurrent hepatocellular cancer: a Western experience[J]. J Hepatol, 2011, 55(2): 346-350. DOI: 10.1016/j.jhep.2010.11.026.
|
[19] |
YAMASHITA Y, SHIRABE K, TSUIJITA E, et al. Third or more repeat hepatectomy for recurrent hepatocellular carcinoma[J]. Surgery, 2013, 154(5): 1038-1045. DOI: 10.1016/j.surg.2013.04.046.
|
[20] |
BALE R, SCHULLIAN P, EBERLE G, et al. Stereotactic radiofrequency ablation of hepatocellular carcinoma: a histopathological study in explanted livers[J]. Hepatology, 2019, 70(3): 840-850. DOI: 10.1002/hep.30406.
|
[21] |
OLIGANE HC, XING M, KIM HS. Effect of bridging local-regional therapy on recurrence of hepatocellular carcinoma and survival after orthotopic liver transplantation[J]. Radiology, 2017, 282(3): 869-879. DOI: 10.1148/radiol.2016160288.
|
[22] |
SAPISOCHIN G, GOLDARACENA N, ASTETE S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series[J]. Ann Surg Oncol, 2015, 22(7): 2286-2294. DOI: 10.1245/s10434-014-4273-6.
|
[23] |
INVERNIZZI F, IAVARONE M, CZAUDERNA C, et al. Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: a real-life multicentre study[J]. Digest Liver Dis, 2019, 51(Suppl 1): e12. DOI: 10.1016/j.dld.2018.11.058.
|
[24] |
KWONG A, KIM WR, LAKE JR, et al. OPTN/SRTR 2018 annual data report: liver[J]. Am J Transplant, 2020, 20(Suppl s1): 193-299. DOI: 10.1111/ajt.15674.
|
[25] |
VIVARELLI M, CUCCHETTI A, PISCAGLIA F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression[J]. Liver Transpl, 2005, 11(5): 497-503. DOI: 10.1002/lt.20391.
|
[26] |
VIVARELLI M, CUCCHETTI A, LA BARBA G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence[J]. Ann Surg, 2008, 248(5): 857-862. DOI: 10.1097/SLA.0b013e3181896278.
|
[27] |
JUNG DH, TAK E, HWANG S, et al. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence[J]. Liver Transpl, 2018, 24(7): 932-945. DOI: 10.1002/lt.25191.
|
[28] |
INVERNIZZI F, IAVARONE M, ZAVAGLIA C, et al. Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation[J]. Transplantation, 2020, 104(3): 568-574. DOI: 10.1097/TP.0000000000002955.
|
[29] |
YANIK EL, CHINNAKOTLA S, GUSTAFSON SK, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma[J]. Liver Transpl, 2016, 22(5): 627-634. DOI: 10.1002/lt.24395.
|
[30] |
贺强, 周林. 构建以雷帕霉素为主预防肝癌肝移植术后肿瘤复发的综合防治体系[J/CD]. 肝癌电子杂志, 2021, 9(3): 1-7. DOI: 10.3969/j.issn.2095-7815.2021.03.001.HE Q, ZHOU L. To establish a comprehensive prevention and treatment system based on rapamycin for cancer recurrence after liver transplantation[J/CD]. Electr J Liver Tumor, 2021, 9(3): 1-7. DOI: 10.3969/j.issn.2095-7815.2021.03.001.
|
[31] |
ABDEL-WAHAB N, SAFA H, ABUDAYYEH A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature[J]. J Immunother Cancer, 2019, 7(1): 106. DOI: 10.1186/s40425-019-0585-1.
|
[32] |
施国明, 黄晓勇, 任正刚, 等. 肝癌免疫检查点抑制剂相关不良反应管理中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594.SHI GM, HUANG XY, REN ZG, et al. Chinese expert consensus on the management of immune-related adverse events of hepatocellular carcinoma treated with immune checkpoint inhibitors (2021 edition)[J]. Chin J Dig Surg, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594.
|
[33] |
SABERIANFAR S, NGUYEN LS, MANOUCHEHRI A, et al. Solid organ transplant rejection associated with immune-checkpoint inhibitors[J]. Ann Oncol, 2020, 31(4): 543-544. DOI: 10.1016/j.annonc.2020.01.012.
|
[34] |
HO CM, CHEN HL, HU RH, et al. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective[J]. Ther Adv Med Oncol, 2019, 11: 1758835919843463. DOI: 10.1177/1758835919843463.
|
[35] |
DELEON TT, SALOMAO MA, AQEL BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience[J]. J Gastrointest Oncol, 2018, 9(6): 1054-1062. DOI: 10.21037/jgo.2018.07.05.
|